View in EDS HTML Full Text PDF Full Text

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.

Saved in:
Bibliographic Details
Title: Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.
Authors: Chen, Xinni1 (AUTHOR), Wang, Feng1 (AUTHOR), Cheng, Yuan1 (AUTHOR), Cao, Mengran1 (AUTHOR), Mei, Kuimin1 (AUTHOR), Chu, Xiaoyuan1 (AUTHOR), Dai, Fang1 (AUTHOR), Gong, Xinlei1 (AUTHOR) xinleigong@qq.com
Source: Clinical & Translational Discovery. Feb2026, Vol. 6 Issue 1, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:27680622
DOI:10.1002/ctd2.70123